<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; HGSI</title>
	<atom:link href="http://www.stockbloghub.com/tag/hgsi/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Still Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209</link>
		<comments>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209#comments</comments>
		<pubDate>Mon, 02 Apr 2012 17:37:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97209</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta in March 2011 for treating patients suffering from systemic lupus erythematosus (SLE) was a huge positive for Human Genome. The subsequent launch of the drug in Canada and several European nations, including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden is also encouraging. Benlysta, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Sales of the drug are growing, albeit slowly. Net sales of Benlysta improved 36.7% sequentially to $25.7 million in the final quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260</link>
		<comments>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260#comments</comments>
		<pubDate>Tue, 01 Nov 2011 20:44:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86260</guid>
		<description><![CDATA[We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected loss due to lower revenues. The most alarming factor was the below-par showing of Human Genome&#8217;s recently launched lupus drug, Benlysta. Following the lackluster showing, we have increased our loss per share estimates for 2011 and 2012. Moreover, management has pushed back its aim of turning profitable by a year to 2014. In view of these headwinds, we see little reason for investors to hold on to the stock at current levels. Our target price is $10.00. HUMAN GENOME (HGSI): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) 2011 Second Quarter Earnings Preview &#8211; Detailed</title>
		<link>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251</link>
		<comments>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251#comments</comments>
		<pubDate>Mon, 18 Jul 2011 21:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABB]]></category>
		<category><![CDATA[ABB Limited]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[ALV]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AmeriServ Financial Inc]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSG]]></category>
		<category><![CDATA[AmSurg Corporation]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AptarGroup Inc.]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[Arbitron Inc]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[ASRV]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT Cross Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[ATR]]></category>
		<category><![CDATA[ATX]]></category>
		<category><![CDATA[Autoliv Inc.]]></category>
		<category><![CDATA[AVID]]></category>
		<category><![CDATA[Avid Technology Inc]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BancFirst Corporation]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Bancorp Rhode Island Inc]]></category>
		<category><![CDATA[BANF]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BARI]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[Ca Technologies]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chicago Bridge & Iron Company N.V.]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cintas Corporation]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[Coca-Cola FEMSA S.A.B de CV]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[COL]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTAS]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[Eastern Virginia Bankshares Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDR]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Education Realty Trust Inc]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Entegris Inc]]></category>
		<category><![CDATA[ENTG]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EVBS]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Fidelity National Information Services Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FIS]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FMX]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Fomento Economico Mexicano S.a.b De C.v.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[Grupo Aeroportuario Centro Norte S.A. de C.V.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[Healthways Inc]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[HWAY]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[KOF]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Landstar System Inc.]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LECO]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Lincoln Electric Holdings]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSTR]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Matthews International Corporation]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MOS]]></category>
		<category><![CDATA[Mosaic Company]]></category>
		<category><![CDATA[MOSY]]></category>
		<category><![CDATA[MoSys Inc]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NAFC]]></category>
		<category><![CDATA[Nash FInch Company]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OFG]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Olin Corporation]]></category>
		<category><![CDATA[OLN]]></category>
		<category><![CDATA[OMAB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oriental Financial Group Inc.]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[PAG]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Penske Automotive Group Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[Plexus Corporation]]></category>
		<category><![CDATA[PLXS]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMC-Sierra Inc.]]></category>
		<category><![CDATA[PMCS]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[Rockwell Collins Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RT]]></category>
		<category><![CDATA[Ruby Tuesday Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[SABA]]></category>
		<category><![CDATA[Saba Software Inc.]]></category>
		<category><![CDATA[Safeway Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Schiff Nutrition International Inc]]></category>
		<category><![CDATA[SCHL]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Scholastic Corporation]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFG]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Sherwin-Williams Company]]></category>
		<category><![CDATA[SHW]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[StanCorp Financial Group Inc.]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[SWY]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Terex Corporation]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[TEX]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[Vitran Corp Inc]]></category>
		<category><![CDATA[VIVO]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VTNC]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>
		<category><![CDATA[Wipro Limited]]></category>
		<category><![CDATA[WIT]]></category>
		<category><![CDATA[WNI]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79251</guid>
		<description><![CDATA[Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&#38;P 500. By next Friday we should have a very good handle on how the overall earnings season will go. The firms reporting this week are sort of like a who&#8217;s who of U.S. industry including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Caterpillar (CAT), General Electric (GE), International Business Machines (IBM), Intel (INTC), McDonald&#8217;s (MCD), Schlumberger (SLB) and Verizon (VZ). That is an interesting cross section of U.S. business. We have a relatively light economic data calendar, so earnings should be front and center, along with the sovereign debt situations on both ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMLS) Company News for March 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582</link>
		<comments>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582#comments</comments>
		<pubDate>Fri, 11 Mar 2011 17:45:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Broadcasting - Radio]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CMLS]]></category>
		<category><![CDATA[Cumulus Media Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GMCR]]></category>
		<category><![CDATA[Green Mountain Coffee Roasters Inc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[IRM]]></category>
		<category><![CDATA[Iron Mountain Inc]]></category>
		<category><![CDATA[LSI]]></category>
		<category><![CDATA[LSI Corporation]]></category>
		<category><![CDATA[National Semiconductor Corporation]]></category>
		<category><![CDATA[NetApp Inc.]]></category>
		<category><![CDATA[NSM]]></category>
		<category><![CDATA[NTAP]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Semtech Corporation]]></category>
		<category><![CDATA[SIGA]]></category>
		<category><![CDATA[SIGA Technologies Inc]]></category>
		<category><![CDATA[SMTC]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68582</guid>
		<description><![CDATA[• Cumulus Media (NASDAQ:CMLS) reported that it has entered into a merger agreement to acquire all the outstanding common stock and warrants of Citadel Broadcasting Corp for $37 per share • Starbucks (NASDAQ:SBUX) and Green Mountain Coffee Roasters (NASDAQ:GMCR) have entered into a strategic relationship for the manufacturing, marketing, distribution and sale of Starbucks and Tazo tea branded K-Cup portion packs for use in the Keurig single-cup brewing system • National Semiconductor (NYSE:NSM) reported Q3 EPS of $0.24, in line with the Zacks Consensus Estimate. Revenues for the quarter fell 12% year-over-year to $343.9 million, lower than the Zacks Consensus Estimate of $352.0 million • Biotech company SIGA Technologies Inc (NASDAQ:SIGA) reported a fourth quarter operating loss of $4.2 million • Late Wednesday NetApp Inc (NASDAQ:NTAP) announced its plans to buy LSI Corporation’s (NYSE:LSI) external ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADSK) Company News for February 25, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/25/adsk-company-news-for-february-25-2011-corporate-summary/67619</link>
		<comments>http://www.stockbloghub.com/2011/02/25/adsk-company-news-for-february-25-2011-corporate-summary/67619#comments</comments>
		<pubDate>Fri, 25 Feb 2011 17:57:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Technical & System Software]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ADSK]]></category>
		<category><![CDATA[Autodesk Inc.]]></category>
		<category><![CDATA[BKD]]></category>
		<category><![CDATA[Brookdale Senior Living Inc.]]></category>
		<category><![CDATA[Crescent Financial Corporation]]></category>
		<category><![CDATA[CRFN]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[IRM]]></category>
		<category><![CDATA[Iron Mountain Inc]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67619</guid>
		<description><![CDATA[• Iron Mountain (NYSE:IRM) reported Q4 EPS of $0.30, ex-items, slightly higher than the Zacks Consensus Estimate of $0.29. • Newmont Mining (NYSE:NEM) reported Q4 EPS of $1.16, ex-items, ahead of the Zacks Consensus Estimate of $1.14 per share • General Motors (NYSE:GM) posted lower than expected Q4 net income of $510 million due to increased spending on new vehicle programs, lower production of high-margin trucks and  IPO related charges incurred last year • Autodesk Inc. (NASDAQ:ADSK) reported Q4 EPS of $0.35, above the Zacks Consensus Estimate of $0.27 per share. Revenues for the quarter rose 16% year-over year to $527.7 million, beating the Zacks Consensus Estimate of $515.0 million • Human Genome Sciences (NASDAQ:HGSI) reported a Q4 EPS loss of $0.46 per share, higher than the Zacks Consensus Estimate for a loss of $0.41 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/25/adsk-company-news-for-february-25-2011-corporate-summary/67619/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Earns FDA Panel Backing of Benlysta</title>
		<link>http://www.stockbloghub.com/2010/11/17/hgsi-human-genome-sciences-earns-fda-panel-backing-of-benlysta/59688</link>
		<comments>http://www.stockbloghub.com/2010/11/17/hgsi-human-genome-sciences-earns-fda-panel-backing-of-benlysta/59688#comments</comments>
		<pubDate>Thu, 18 Nov 2010 04:37:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59688</guid>
		<description><![CDATA[Human Genome Sciences Inc. (HGSI) received a huge boost when its potential blockbuster candidate Benlysta received a positive recommendation from an advisory panel of the US Food and Drug Administration (FDA). The Arthritis Advisory Committee voted 13-2 in favor of approving Benlysta for the treatment of patients suffering from systemic lupus erythematosus (SLE). In addition to asking the panel to discuss the efficacy data, the FDA had asked the panel to discuss the safety profile of the drug as well. The panel was asked to concentrate on the safety signals of infection, malignancy, suicidality, and mortality imbalance favoring placebo over Benlysta. Apart from that, the panel was also asked to weigh the risks of using Benlysta in combination with other immunosuppressive agents. A final decision from the FDA should be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/hgsi-human-genome-sciences-earns-fda-panel-backing-of-benlysta/59688/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Reports Narrower Than Expected Earnings Loss</title>
		<link>http://www.stockbloghub.com/2010/10/30/hgsi-human-genome-sciences-reports-narrower-than-expected-earnings-loss/57137</link>
		<comments>http://www.stockbloghub.com/2010/10/30/hgsi-human-genome-sciences-reports-narrower-than-expected-earnings-loss/57137#comments</comments>
		<pubDate>Sat, 30 Oct 2010 18:16:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57137</guid>
		<description><![CDATA[Human Genome Sciences Inc.’s (HGSI) third quarter 2010 loss of 22 cents per share was narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 32 cents. The narrower loss in the reported quarter was attributable to the massive jump in revenues recorded in the quarter. Revenues in the reported quarter climbed 170.2% to $50.8 million in the reported quarter easily surpassing the Zacks Consensus Revenue Estimate of $31 million. The massive jump recorded in the quarter was attributable to the increase in revenues recognized due to the decision of Human Genome and partner Novartis (NVS) to terminate the development of Zalbin for treating hepatitis C. The decision, which caused Human Genome to recognize the entire remaining deferred revenue under the deal during ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/30/hgsi-human-genome-sciences-reports-narrower-than-expected-earnings-loss/57137/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Earns Priority Review for Benlysta</title>
		<link>http://www.stockbloghub.com/2010/08/22/hgsi-human-genome-sciences-earns-priority-review-for-benlysta/48699</link>
		<comments>http://www.stockbloghub.com/2010/08/22/hgsi-human-genome-sciences-earns-priority-review-for-benlysta/48699#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:23:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48699</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) received a huge boost when its potential blockbuster drug candidate Benlysta was granted priority review status by the US Food and Drug Administration (FDA). Benlysta, co-developed by Human Genome and GlaxoSmithKline plc (GSK), has been developed for the treatment of patients suffering from systemic lupus erythematosus (SLE). The US regulatory authority generally reviews those drugs on a priority basis, which offer major advances in treating diseases having no adequate therapy. Applications for priority review designated drugs are reviewed by the FDA within six months of submission instead of the usual ten months. Consequently, a response from the FDA should be out in the fourth quarter of 2010 (projected target date: December 9, 2010). The Biologics License Application (BLA) seeking marketing approval for the lupus candidate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/hgsi-human-genome-sciences-earns-priority-review-for-benlysta/48699/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Seeks Lupus Drug FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/06/13/hgsi-human-genome-sciences-seeks-lupus-drug-fda-approval/40134</link>
		<comments>http://www.stockbloghub.com/2010/06/13/hgsi-human-genome-sciences-seeks-lupus-drug-fda-approval/40134#comments</comments>
		<pubDate>Sun, 13 Jun 2010 23:47:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=40134</guid>
		<description><![CDATA[Human Genome Sciences Inc. (HGSI) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for its potential blockbuster lupus drug candidate, Benlysta. Human Genome and GlaxoSmithKline plc (GSK) are co-developing Benlysta for treating patients suffering from systemic lupus erythematosus (SLE). We remind investors that Benlysta, a human monoclonal antibody that specifically recognizes and prevents the biological activity of the naturally occurring protein B-lymphocyte stimulator (BLyS), met the primary endpoint in the BLISS-52 trial in 2009. Furthermore, Benlysta met the primary end-point in BLISS-76 through 52 weeks in November 2009. However, Benlysta did not prove to be more effective than placebo in the long-term according to the complete 76-week data from the BLISS-76 trial announced earlier this year. The two studies evaluated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/13/hgsi-human-genome-sciences-seeks-lupus-drug-fda-approval/40134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Seeks European Approval For Lupus Drug</title>
		<link>http://www.stockbloghub.com/2010/06/09/hgsi-human-genome-sciences-seeks-european-approval-for-lupus-drug/39731</link>
		<comments>http://www.stockbloghub.com/2010/06/09/hgsi-human-genome-sciences-seeks-european-approval-for-lupus-drug/39731#comments</comments>
		<pubDate>Wed, 09 Jun 2010 13:07:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=39731</guid>
		<description><![CDATA[Human Genome Sciences Inc. (HGSI) recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking marketing approval for its potential blockbuster lupus drug candidate, Benlysta, in Europe. Human Genome and GlaxoSmithKline plc (GSK) are co-developing Benlysta for treating patients suffering from systemic lupus erythematosus (SLE). The application includes data from the two late-stage trials, BLISS-52 and BLISS-76. Both double-blind, placebo-controlled, multi-center studies evaluated the efficacy and safety of Benlysta in combination with the standard of care against placebo plus standard of care, in seropositive SLE patients. The studies evaluated a total of 1,684 patients. We remind investors that Benlysta, a human monoclonal antibody that specifically recognizes and prevents the biological activity of B-lymphocyte stimulator (BLyS), met the primary endpoint in the BLISS-52 trial in 2009. Furthermore, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/09/hgsi-human-genome-sciences-seeks-european-approval-for-lupus-drug/39731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences&#8217; Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/23/hgsi-human-genome-sciences-earnings-scorecard/37594</link>
		<comments>http://www.stockbloghub.com/2010/05/23/hgsi-human-genome-sciences-earnings-scorecard/37594#comments</comments>
		<pubDate>Mon, 24 May 2010 04:24:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37594</guid>
		<description><![CDATA[Human Genome Sciences, Inc.’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of a loss of 20 cents. The company earned 56 cents in the year-ago quarter. We believe that the earnings report at Human Genome is a non-event. This is because investor focus is more on the company’s interesting and diversified pipeline. Consequently, our take is that the lowering of earnings estimates over the past 30 days by a majority of the analysts covering the stock has more to do with the recent pipeline setbacks at Human Genome rather than the earnings report. Earnings Report Review The loss suffered in the reported quarter was attributable to lower revenues primarily on account of a drop in sales of ABthrax (for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/23/hgsi-human-genome-sciences-earnings-scorecard/37594/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Reports Wider-Than-Expected Loss</title>
		<link>http://www.stockbloghub.com/2010/05/03/hgsi-human-genome-sciences-reports-wider-than-expected-loss/35893</link>
		<comments>http://www.stockbloghub.com/2010/05/03/hgsi-human-genome-sciences-reports-wider-than-expected-loss/35893#comments</comments>
		<pubDate>Mon, 03 May 2010 21:50:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35893</guid>
		<description><![CDATA[Human Genome Sciences Inc’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of 20 cents. The company earned 56 cents per share (excluding special items) in the year-ago quarter. The loss suffered in the reported quarter was attributable to lower revenues primarily because of a drop in sales of ABthrax (for the treatment of inhalation anthrax) to the U.S. Strategic National Stockpile. Revenue in the reported quarter plummeted to $46.5 million as against $177.3 million in the year-ago quarter. Revenue for the quarter included $27.6 million related to the global agreement with Novartis (NVS) for the development of Zalbin to treat Hepatitis C. Revenue recognized from the sale of ABthrax dropped to $13.5 million in the reported quarter as against ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/03/hgsi-human-genome-sciences-reports-wider-than-expected-loss/35893/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Announces Bad News for Lupus Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-announces-bad-news-for-lupus-candidate/34558</link>
		<comments>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-announces-bad-news-for-lupus-candidate/34558#comments</comments>
		<pubDate>Wed, 21 Apr 2010 20:21:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34558</guid>
		<description><![CDATA[Recently, Human Genome Sciences, Inc. (HGSI) announced that its potential blockbuster lupus drug candidate Benlysta (belimumab) failed to meet its secondary goals in a late-stage trial BLISS-76. Human Genome and GlaxoSmithKline plc (GSK) are co-developing Benlysta for treating patients suffering from systemic lupus erythematosus (SLE). Lupus, an inflammatory disease, causes the body&#8217;s immune system to attack its own tissues and organs. Benlysta, a human monoclonal antibody, is designed to suppress the body&#8217;s immune response to lupus. BLISS-76 is the second of two pivotal phase III trials in patients with active SLE. The double-blind, placebo-controlled, multi-center trial evaluated the efficacy and safety of Benlysta plus standard of care compared to placebo plus standard of care for treating SLE patients. The study revealed that at Week 76 Benlysta plus standard of care ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-announces-bad-news-for-lupus-candidate/34558/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Gets Setback From Partner Novartis AG</title>
		<link>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-gets-setback-from-partner-novartis-ag/34445</link>
		<comments>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-gets-setback-from-partner-novartis-ag/34445#comments</comments>
		<pubDate>Wed, 21 Apr 2010 15:37:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34445</guid>
		<description><![CDATA[Recently, Human Genome Sciences Inc. (HGSI) received a setback when the Marketing Authorization Application (MAA) for its hepatitis C candidate Joulferon (albinterferon alfa-2b) was withdrawn by its partner Novartis AG (NVS). Novartis, with whom Human Genome entered into an exclusive global agreement for the development and commercialization of the drug in 2006, submitted the MAA to the European Medicines Agency (EMEA) for its hepatitis C candidate in December 2009. Human Genome and Novartis have selected “Zalbin&#8221; as the brand name for albinterferon alfa- 2b in the United States while “Joulferon&#8221; is the brand name for the rest of the world. The drug is under review in the United States. Human Genome submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in November 2009. The company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/hgsi-human-genome-sciences-gets-setback-from-partner-novartis-ag/34445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Releases Encouraging Data on Zalbin</title>
		<link>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742</link>
		<comments>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742#comments</comments>
		<pubDate>Thu, 25 Mar 2010 22:45:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31742</guid>
		<description><![CDATA[Recently, Human Genome Sciences Inc. (HGSI) announced interim results on hepatitis C candidate Zalbin from a mid-stage study. The study evaluated the safety and efficacy of Zalbin. The results revealed that a monthly dose of Zalbin was as effective as a weekly dose of Roche’s (RHHBY) Pegasys (peginterferon alfa-2a), which is the current standard of care. The study combined Zalbin with ribavirin in 391 treatment-naive patients infected with genotypes 2 and 3 hepatitis C. Full results from the study are expected to be presented later in the year. The subjects enrolled for the mid-stage study were randomized in a 4:4:4:3 ratio into four treatment groups. Patients in three groups received Zalbin, administered once a month (900 mcg, 1200 mcg or 1500 mcg). Patients in the other group received Pegasys at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Joins Forces With Swedish To Commercialize New Drugs</title>
		<link>http://www.stockbloghub.com/2010/03/12/hgsi-human-genome-sciences-joins-forces-with-swedish-to-commercialize-new-drugs/30528</link>
		<comments>http://www.stockbloghub.com/2010/03/12/hgsi-human-genome-sciences-joins-forces-with-swedish-to-commercialize-new-drugs/30528#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:19:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30528</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) and BioInvent International AB, a Swedish pharmaceutical research company, have joined forces to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by Human Genome. However, the financial terms of the transaction were undisclosed. Under the terms of the agreement, the Swedish firm will apply its antibody discovery technology for generating and developing monoclonal antibody candidates. The deal will initially focus towards developing antibodies in the field of inflammation. Both the parties have agreed to share costs related to research, development and commercialization and any potential revenue. The partnership with the Swedish firm will provide a perfect opportunity to Human Genome to advance its pipeline and develop potential new drugs based on discoveries made by Human Genome. The Swedish firm already possesses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/hgsi-human-genome-sciences-joins-forces-with-swedish-to-commercialize-new-drugs/30528/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Reports Lower Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/03/03/hgsi-human-genome-sciences-reports-lower-fourth-quarter-loss/29564</link>
		<comments>http://www.stockbloghub.com/2010/03/03/hgsi-human-genome-sciences-reports-lower-fourth-quarter-loss/29564#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:37:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29564</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of $61.9 million or 46 cents. The reduced net loss for the quarter was primarily attributable to increased revenues and lower operating expenses. Quarterly Results Revenue in the reported quarter jumped to $53.0 million from $12.9 million in the year-ago quarter. Revenue for the quarter included $27.6 million related to the global agreement with Novartis (NVS) for the development of Zalbin (formerly Albuferon) to treat Hepatitis C. Furthermore, revenue for the reported quarter also included $17.7 million recognized from the sales and delivery of ABthrax (raxibacumab) &#8211; the company&#8217;s candidate for anthrax treatment &#8211; to the U.S. Strategic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/hgsi-human-genome-sciences-reports-lower-fourth-quarter-loss/29564/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Pipeline Bigger than Earnings</title>
		<link>http://www.stockbloghub.com/2010/02/25/hgsi-human-genome-sciences-pipeline-bigger-than-earnings/29027</link>
		<comments>http://www.stockbloghub.com/2010/02/25/hgsi-human-genome-sciences-pipeline-bigger-than-earnings/29027#comments</comments>
		<pubDate>Thu, 25 Feb 2010 20:31:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29027</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) is expected to report fourth quarter as well as fiscal 2009 results shortly. We expect that the company will report a loss of 10 cents per share for the fourth quarter of 2009 and 4 cents for fiscal 2009. However, we believe that the earnings report is basically a non-event for the company and will have little or no impact on the stock price. We feel that investors are more concerned about the progress of the company’s pipeline candidates, especially Benlysta. Human Genome boasts a robust pipeline with three late-stage candidates. Human Genome Sciences intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States and Europe. We expect US approval in early 2011. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/hgsi-human-genome-sciences-pipeline-bigger-than-earnings/29027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) These Biotech Stocks Are Just What the Doctor Ordered</title>
		<link>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383</link>
		<comments>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:47:12 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[Generex Biotechnology Corporation]]></category>
		<category><![CDATA[GNBT]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26383</guid>
		<description><![CDATA[by Louise Harris, Investment U Research Thursday, January 28, 2010 They say that one in every nine women will get breast cancer. It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some type of cancer in their lifetimes… or that the disease affects 10 million people around the globe every year. Fortunately, doctors, research teams and entire corporations have set their brilliant minds to finding a viable cure. And they’ve made enormous strides in DNA profiling and the emerging field of pharmacogenomics – which studies how individual genetics affect medication outcomes. Meanwhile, other companies are developing prophylactic vaccines, which target viruses that lead to cancer. Kalorama Information expects the market to double from the $2 billion recorded in 2008 to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/dndn-these-biotech-stocks-are-just-what-the-doctor-ordered/26383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences to Seek Drug Approval in Second Quarter</title>
		<link>http://www.stockbloghub.com/2010/01/14/hgsi-human-genome-sciences-to-seek-drug-approval-in-second-quarter/24981</link>
		<comments>http://www.stockbloghub.com/2010/01/14/hgsi-human-genome-sciences-to-seek-drug-approval-in-second-quarter/24981#comments</comments>
		<pubDate>Thu, 14 Jan 2010 19:14:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24981</guid>
		<description><![CDATA[Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States and Europe. Human Genome and GlaxoSmithKline plc (GSK) are co-developing Benlysta for treating patients suffering from systemic lupus erythematosus (SLE). We remind investors that in Nov 2009, Benlysta met the primary end-point in BLISS-76, a pivotal phase III study, through 52 weeks. BLISS-76 is the second phase III trial in seropositive SLE patients. Complete 76-week data from the trial are expected to be available in the second quarter of 2010. Positive results from the first trial, BLISS-52, were announced in the third quarter of 2009. These results bring the company a step closer to becoming the first to have ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/hgsi-human-genome-sciences-to-seek-drug-approval-in-second-quarter/24981/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Seeks Approval For Hepatitis C Treatment</title>
		<link>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016</link>
		<comments>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:27:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23016</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) recently announced the submission of a Marketing Authorization Application, [MAA], to the European Medicines Agency (EMEA) seeking marketing approval of Joulferon (albinterferon alfa-2b) for treating chronic hepatitis C patients. The application was submitted by Novartis (NVS) with whom Human Genome entered into an exclusive global agreement for the development and commercialization of the drug in 2006. The application  for European approval includes data from two pivotal late-stage trials which showed that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys of Roche (RHHBY)) dosed once each week. The randomized, open-label, active-controlled, multi-center, non-inferiority studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for treating interferon-naïve patients with chronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences to Sell 12.5 Million Shares</title>
		<link>http://www.stockbloghub.com/2009/12/02/hgsi-human-genome-sciences-to-sell-12-5-million-shares/21745</link>
		<comments>http://www.stockbloghub.com/2009/12/02/hgsi-human-genome-sciences-to-sell-12-5-million-shares/21745#comments</comments>
		<pubDate>Wed, 02 Dec 2009 20:38:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21745</guid>
		<description><![CDATA[Human Genome Sciences Inc. (HGSI) announced that it intends to sell up to 12.5 million shares to raise money for the development of its potential blockbuster lupus drug Benlysta and other business activities. The net proceeds from the public offering will be used for general corporate purposes, which include the acquisition of additional manufacturing capacity and development of new indications for Benlysta. The underwriters of the offering have a 30-day option to purchase another 1.9 million shares to cover over-allotments. Human Genome forecasted its operating expenses, after collaboration partner reimbursements, to increase from $250 million in 2009 to a range of about $325 million- $375 million in 2010. The increase is primarily attributable to the pre-launch manufacturing expenses associated with Benlysta coupled with increased sales and marketing expenses. As a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/hgsi-human-genome-sciences-to-sell-12-5-million-shares/21745/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Begins Trial</title>
		<link>http://www.stockbloghub.com/2009/11/25/hgsi-human-genome-sciences-begins-trial/21294</link>
		<comments>http://www.stockbloghub.com/2009/11/25/hgsi-human-genome-sciences-begins-trial/21294#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:17:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21294</guid>
		<description><![CDATA[Recently, Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis protein (IAP), HGS1029, as monotherapy in patients with advanced lymphoid tumors. An additional phase I clinical trial of the compound is being conducted to evaluate its safety and tolerability in patients with advanced solid tumors. Earlier in December 2007, Human Genome acquired exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 and other IAPs from Aegera Therapeutics. The primary objectives of the phase I open-label, dose-escalation study include the evaluation of safety and tolerability of HGS1029 as monotherapy in patients with advanced lymphoid tumors and selection of a recommended dose for further studies. In addition, secondary objectives include studying ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/hgsi-human-genome-sciences-begins-trial/21294/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences&#8217; ABthrax Faces FDA Delay</title>
		<link>http://www.stockbloghub.com/2009/11/17/hgsi-human-genome-sciences-abthrax-faces-fda-delay/20788</link>
		<comments>http://www.stockbloghub.com/2009/11/17/hgsi-human-genome-sciences-abthrax-faces-fda-delay/20788#comments</comments>
		<pubDate>Tue, 17 Nov 2009 22:22:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20788</guid>
		<description><![CDATA[Recently, Human Genome Sciences Inc. (HGSI) announced that the U.S. Food and Drug Administration (FDA) delayed the approval of ABthrax (raxibacumab), the company’s candidate for anthrax treatment, asking for additional information pertaining to the drug. The agency issued a complete response letter wherein it asked for additional information in response to the Biologics License Application (BLA) filed in May 2009. The company intends to provide the agency with the requested information shortly. The agency’s decision comes weeks after an FDA advisory panel questioned the drug’s effectiveness when compared to existing anti-bacterial drugs since ABthrax was primarily tested in animals, not humans. Late last month, the panel of experts voted 17 to 6, with one abstention, that the company should submit more evidence on whether adding ABthrax to older drugs is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/17/hgsi-human-genome-sciences-abthrax-faces-fda-delay/20788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Reports Lower Q3 Loss</title>
		<link>http://www.stockbloghub.com/2009/11/07/hgsi-human-genome-sciences-reports-lower-q3-loss/19795</link>
		<comments>http://www.stockbloghub.com/2009/11/07/hgsi-human-genome-sciences-reports-lower-q3-loss/19795#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:39:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19795</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating expenses. Revenues for the quarter came in at $18.834 million which reflected an increase of 60.6%. Revenues were inclusive of $8.7 million from manufacturing and development services, $8.9 million recognized under the company’s agreement with Novartis (NVS) pertaining to hepatitis C drug Zalbin, and $1.0 million recognized under the agreement with GlaxoSmithKline plc (GSK) pertaining to the potential blockbuster lupus drug Benlysta. Research &#38; development spend declined 36% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/hgsi-human-genome-sciences-reports-lower-q3-loss/19795/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Gets FDA Panel Request for ABthrax Data</title>
		<link>http://www.stockbloghub.com/2009/11/01/hgsi-human-genome-sciences-gets-fda-panel-request-for-abthrax-data/19311</link>
		<comments>http://www.stockbloghub.com/2009/11/01/hgsi-human-genome-sciences-gets-fda-panel-request-for-abthrax-data/19311#comments</comments>
		<pubDate>Sun, 01 Nov 2009 22:02:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19311</guid>
		<description><![CDATA[A panel of experts of the US Food and Drug Administration (FDA) has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc.’s (HGSI) anthrax infection treatment ABthrax (raxibacumab) compared to existing anti-bacterial drugs. The panel of experts voted 17 to 6, with one abstention, that the company should submit more evidence on whether adding ABthrax to older drugs is beneficial for anthrax treatment. Data from studies had revealed that antibiotic medicines used alone were highly effective against anthrax, thereby raising questions about the added benefit of ABthrax. Furthermore, the drug appeared to be effective when used with antibiotics in rabbits and monkeys. The same panel also voted in favor of using data from the animal studies to predict how the drug will work in humans. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/hgsi-human-genome-sciences-gets-fda-panel-request-for-abthrax-data/19311/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Drug Under FDA Review</title>
		<link>http://www.stockbloghub.com/2009/10/28/hgsi-human-genome-sciences-drug-under-fda-review/19138</link>
		<comments>http://www.stockbloghub.com/2009/10/28/hgsi-human-genome-sciences-drug-under-fda-review/19138#comments</comments>
		<pubDate>Thu, 29 Oct 2009 04:44:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19138</guid>
		<description><![CDATA[Recently, Human Genome Sciences Inc. (HGSI) suffered a setback when the US Food and Drug Administration (FDA) questioned the efficacy of its drug ABthrax (raxibacumab), meant for treating anthrax infection. The FDA accepted that the medication was more effective than a placebo in treating anthrax exposure in animals. However, it was unsure as to how effective the treatment would be for humans since the reliability of human data is doubtful. Though the drug appeared to be effective when used with antibiotics in rabbits and monkeys, animal studies do not always predict success in humans. Later today, an advisory panel from the FDA is scheduled to meet to decide whether the benefits of the drug outweigh the risks for treating deadly infections caused by anthrax inhalation. As a reminder, Human Genome ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/hgsi-human-genome-sciences-drug-under-fda-review/19138/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

